This article is more than 5 years old. Information may no longer be current.

FDA clears implant for treatment of distal radius fractures

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Conventus Orthopaedics announced that it has received 510(k) clearance to market its Conventus DRS Implant for the treatment of distal radius fractures within the United States.

According to a press release, the Conventus DRS Implant is designed to provide a less invasive means for orthopaedic surgeons to treat patients with distal radius fractures, returning them to normal daily activities sooner and with less pain. The implant is self-expanding and stabilizes the fracture fragments from within the bone and the surgical procedure requires only a 2-cm to 3-cm incision on the forearm and a few tiny incisions at the wrist, reducing trauma by as much as 80%. The technique also preserves soft tissue around the fracture to minimize stiffness, swelling and pain.

“Conventus is very pleased to bring this innovative technology to the U.S. expanding the possibilities for quality patient care,” Paul Hindrichs, chief executive officer of Conventus Orthopaedics, stated in a company press release. “The results from our European clinical study indicate that this will be a very successful technology for distal radius fractures in the US and around the globe.”